Because low Hb is a potentially modifiable factor, its identification in patients with coronary or valvular heart disease, or who are to undergo elective surgery, would eventually help to design therapeutic regimens designed to correct the Hb level and then assess the impact of this treatment on postoperative outcomes. This evidence concerns the gene GSTM1 and heart valve disorder.